Literature DB >> 15205239

Transporter associated protein expression in uveal melanoma.

S Krishnakumar1, S A Lakshmi, D Abhyankar, J Biswas.   

Abstract

BACKGROUND/AIM: Transporter associated protein (TAP) is important for presenting peptides to major histocompatibility complex (MHC) class I molecules. Defects in TAP lead to decreased MHC class I expression. The immunoexpression of human leucocyte antigen (HLA) class I molecules and the TAP1 subunit were studied in primary uveal melanomas and correlated with the cell types and extrascleral extension.
METHODS: The HLA class I antigen and TAP1 subunit were analysed by immunoperoxidase staining with monoclonal antibodies on 45 primary uveal melanoma archival specimens. The tumours were divided into two groups-group A: tumours with no extrascleral extension; group B tumours with extrascleral extension/liver metastasis. Immunoanalysis was done by a semiquantitative method.
RESULTS: HLA class I antigen and TAP1 were decreased in 35 of 35 tumours with no extrascleral extension and positive in six of 10 tumours with liver metastasis. Decreased immunoexpression of HLA class I antigen and TAP1 in uveal melanomas with no extrascleral extension was significant (p<0.001). HLA class I antigen and TAP1 were negative in spindle cell melanomas (p<0.001).
CONCLUSIONS: HLA class I antigen and TAP1 expression were decreased in uveal melanomas with no extrascleral extension and in spindle cell melanomas. Decreased expression of TAP1 may lead to decreased expression of HLA class I antigen in uveal melanomas. This preliminary observation deserves further investigation, which may shed more light on the immune escape mechanisms of this tumour and thus enable novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205239      PMCID: PMC1772238          DOI: 10.1136/bjo.2003.018457

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  Uveal melanoma in Asian Indians: a clinicopathological study.

Authors:  Jyotirmay Biswas; Subramanian Krishnakumar; Mahesh P Shanmugam
Journal:  Arch Ophthalmol       Date:  2002-04

2.  Assembly and cell surface expression of TAP-independent, chloroquine-sensitive and interferon-gamma-inducible class I MHC complexes in transformed fibroblast cell lines are regulated by tapasin.

Authors:  Sharon Vigodman Fromm; Shirly Duady-Ben Yaakov; Chana Schechter; Rachel Ehrlich
Journal:  Cell Immunol       Date:  2002-02       Impact factor: 4.868

Review 3.  TAP off--tumors on.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  1997-06

Review 4.  HLA expression in uveal melanoma: there is no rule without some exception.

Authors:  Martine J Jager; H Monique H Hurks; Jelena Levitskaya; Rolf Kiessling
Journal:  Hum Immunol       Date:  2002-06       Impact factor: 2.850

Review 5.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

6.  Association of HLA class I and class II antigen expression and mortality in uveal melanoma.

Authors:  C Ericsson; S Seregard; A Bartolazzi; E Levitskaya; S Ferrone; R Kiessling; O Larsson
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

7.  Diffuse malignant melanoma of the choroid simulating metastatic tumour in the choroid.

Authors:  J Biswas; R Raghavendra; V Ratra; S Krishnakumar; L Gopal; M P Shanmugam
Journal:  Indian J Ophthalmol       Date:  2000-06       Impact factor: 1.848

8.  Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.

Authors:  A K Johnsen; D J Templeton; M Sy; C V Harding
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

9.  Survival in metastatic ocular melanoma.

Authors:  S Rajpal; R Moore; C P Karakousis
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

10.  Prognosis and treatment of disseminated uveal melanoma.

Authors:  R Kath; J Hayungs; N Bornfeld; W Sauerwein; K Höffken; S Seeber
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.